Vitamin D and Parkinson's disease—A hypothesis
暂无分享,去创建一个
[1] W. Koller,et al. Falls and Parkinson's disease. , 1989, Clinical neuropharmacology.
[2] G. Román,et al. Worldwide occurrence of Parkinson's disease: an updated review. , 1993, Neuroepidemiology.
[3] B. Hoffer,et al. Vitamin D3 attenuates 6-hydroxydopamine-induced neurotoxicity in rats , 2001, Brain Research.
[4] R. Vieth,et al. Wintertime vitamin D insufficiency is common in young Canadian women, and their vitamin D intake does not prevent it , 2001, European Journal of Clinical Nutrition.
[5] J. McNeal,et al. Reduced 1alpha-hydroxylase activity in human prostate cancer cells correlates with decreased susceptibility to 25-hydroxyvitamin D3-induced growth inhibition. , 2001, Cancer research.
[6] S. Ozgoçmen,et al. Vitamin D deficiency and reduced bone mineral density in multiple sclerosis: effect of ambulatory status and functional capacity , 2005, Journal of Bone and Mineral Metabolism.
[7] P. Elias,et al. 25 Hydroxyvitamin D 1 alpha-hydroxylase is required for optimal epidermal differentiation and permeability barrier homeostasis. , 2004, The Journal of investigative dermatology.
[8] S. Brimijoin,et al. 1,25-Dihydroxyvitamin D3 receptors in the central nervous system of the rat embryo , 1998, Brain Research.
[9] S. P. Chow,et al. Sequential fractures of both hips in elderly patients--a prospective study. , 1992, The Journal of trauma.
[10] T. Veenstra,et al. Distribution of 1,25-dihydroxyvitamin D3 receptor immunoreactivity in the rat brain and spinal cord , 1999, Journal of Chemical Neuroanatomy.
[11] F. Sim,et al. Prosthetic replacement of the femoral head for fracture of the femoral neck in patients who have Parkinson disease. , 1988, The Journal of bone and joint surgery. American volume.
[12] C. Barton,et al. Vitamin D fortification in the United States and Canada: current status and data needs. , 2004, The American journal of clinical nutrition.
[13] Carly M. Kemmis,et al. Human mammary epithelial cells express CYP27B1 and are growth inhibited by 25-hydroxyvitamin D-3, the major circulating form of vitamin D-3. , 2006, The Journal of nutrition.
[14] J. McGrath,et al. Distribution of the Vitamin D receptor and 1α-hydroxylase in human brain , 2005, Journal of Chemical Neuroanatomy.
[15] P. Trouillas,et al. Reversible parkinsonism, hypophosphoremia, and hypocalcemia under vitamin D therapy , 1997, Movement disorders : official journal of the Movement Disorder Society.
[16] L. Chia,et al. Bone mineral density in patients with Parkinson's disease measured by dual photon absorptiometry , 1994, Nuclear medicine communications.
[17] D. Zehnder,et al. Vitamin D and barrier function: a novel role for extra-renal 1α-hydroxylase , 2004, Molecular and Cellular Endocrinology.
[18] A. Howie,et al. The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright © 2001 by The Endocrine Society Extrarenal Expression of 25-Hydroxyvitamin , 2022 .
[19] François Berger,et al. New clues about vitamin D functions in the nervous system , 2002, Trends in Endocrinology & Metabolism.
[20] P. Goldberg. Multiple sclerosis: vitamin D and calcium as environmental determinants of prevalence: (A viewpoint) part 2. biochemical and genetic factors , 1974 .
[21] W. Rocca,et al. Prevalence of Parkinson's disease in junín, Buenos Aires province, argentina , 1997, Movement disorders : official journal of the Movement Disorder Society.
[22] C. Buncher,et al. Birthplace as a risk factor in motor neurone disease and Parkinson's disease. , 1993, International journal of epidemiology.
[23] A. Sadovnick,et al. Vitamin D intake and incidence of multiple sclerosis , 2004, Neurology.
[24] T. Hayashi,et al. Vitamin D3 attenuates cortical infarction induced by middle cerebral arterial ligation in rats , 2000, Neuropharmacology.
[25] A. Norman. Sunlight, season, skin pigmentation, vitamin D, and 25-hydroxyvitamin D: integral components of the vitamin D endocrine system. , 1998, The American journal of clinical nutrition.
[26] J. Kurtzke,et al. Parkinsonism death rates by race, sex, and geography , 1988, Neurology.
[27] J. De Pedro-Cuesta,et al. Prevalence of Parkinson's disease in lower Aragon, Spain , 1999, Movement disorders : official journal of the Movement Disorder Society.
[28] C. Weaver,et al. Vitamin D requirements: current and future. , 2004, The American journal of clinical nutrition.
[29] M. Holick,et al. Vitamin D: importance in the prevention of cancers, type 1 diabetes, heart disease, and osteoporosis. , 2004, The American journal of clinical nutrition.
[30] H. Bidmon,et al. Vitamin d nuclear binding to neurons of the septal, substriatal and amygdaloid area in the siberian hamster (Phodopus sungorus) brain , 1992, Neuroscience.
[31] Kwang-Soo Lee,et al. Association of Vitamin D Receptor Gene Polymorphism and Parkinson's Disease in Koreans , 2005, Journal of Korean medical science.
[32] P. Goldberg. Multiple sclerosis: vitamin D and calcium as environmental determinants of prevalence. (A viewpoint). Part 1. Sunlight, dietary factors and epidemiology. , 1974 .
[33] M. F. Stewart,et al. Constitutive synthesis of 1,25-dihydroxyvitamin D3 by a human small cell lung cancer cell line. , 1994, The Journal of clinical endocrinology and metabolism.
[34] J. Aita,et al. Why patients with Parkinson's disease fall. , 1982, JAMA.
[35] Mary Frances Picciano,et al. Dietary supplement use by US adults: data from the National Health and Nutrition Examination Survey, 1999-2000. , 2004, American journal of epidemiology.
[36] W. Stumpf,et al. 1,25(OH)2 vitamin D3 sites of action in the brain , 1987, Histochemistry.
[37] M. Calvo,et al. Dietary recommendations to meet both endocrine and autocrine needs of Vitamin D , 2005, The Journal of Steroid Biochemistry and Molecular Biology.
[38] R. Koerfer,et al. Putting cardiovascular disease and vitamin D insufficiency into perspective , 2005, British Journal of Nutrition.
[39] Intakes for Calcium , Phosphorus , Magnesium , Vitamin D , and Fluoride , 1974 .
[40] A. Chaudhuri. Why we should offer routine vitamin D supplementation in pregnancy and childhood to prevent multiple sclerosis. , 2005, Medical hypotheses.
[41] J. McGrath,et al. Vitamin D: the neglected neurosteroid? , 2001, Trends in Neurosciences.
[42] L. Airas,et al. 25-Hydroxyvitamin D levels in serum at the onset of multiple sclerosis , 2005, Multiple sclerosis.
[43] J. Kurtzke,et al. Is Parkinson's disease acquired? Evidence from a geographic comparison with multiple sclerosis , 1987, Neurology.
[44] J. Y. Wang,et al. Vitamin D(3) attenuates 6-hydroxydopamine-induced neurotoxicity in rats. , 2001, Brain research.
[45] M. Cantorna,et al. Mounting Evidence for Vitamin D as an Environmental Factor Affecting Autoimmune Disease Prevalence , 2004, Experimental biology and medicine.
[46] B. Djahanguiri,et al. The prevention of acute gastric ulcer in the rat by alpha-methyldopa. , 1967, Medicina et pharmacologia experimentalis. International journal of experimental medicine.
[47] E. Bajna,et al. 25-Hydroxyvitamin D3-1α-hydroxylase and vitamin D receptor gene expression in human colonic mucosa is elevated during early cancerogenesis , 2001, Steroids.
[48] M. Holick. Sunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers, and cardiovascular disease. , 2004, The American journal of clinical nutrition.
[49] A. Zittermann. Vitamin D in preventive medicine: are we ignoring the evidence? , 2003, The British journal of nutrition.
[50] B. Hollis. Circulating 25-hydroxyvitamin D levels indicative of vitamin D sufficiency: implications for establishing a new effective dietary intake recommendation for vitamin D. , 2005, The Journal of nutrition.
[51] W. Pardridge,et al. Restricted Transport of Vitamin D and A Derivatives Through the Rat Blood‐Brain Barrier , 1985, Journal of neurochemistry.
[52] T. Veenstra,et al. 1,25-dihydroxyvitamin D3 regulates the expression of N-myc, c-myc, protein kinase C, and transforming growth factor-beta2 in neuroblastoma cells. , 1997, Biochemical and biophysical research communications.
[53] D. Raiten,et al. Vitamin D and health in the 21st century: bone and beyond. Executive summary. , 2004, The American journal of clinical nutrition.
[54] Yoshihiro Sato,et al. Risk factors for hip fracture among elderly patients with Parkinson’s disease , 2001, Journal of the Neurological Sciences.
[55] A. Embry. Vitamin D Supplementation in the Fight Against Multiple Sclerosis , 2022 .
[56] J L Kelsey,et al. Risk factors for falls as a cause of hip fracture in women. The Northeast Hip Fracture Study Group. , 1991, The New England journal of medicine.
[57] A. Mackay-Sim,et al. Vitamin d3 and brain development , 2003, Neuroscience.
[58] P. Brachet,et al. 1,25‐Dihydroxyvitamin D3, an inducer of glial cell line‐derived neurotrophic factor , 1996, Neuroreport.
[59] S. Kikuchi,et al. Effect of 1,25‐dihydroxyvitamin D3 on cultured mesencephalic dopaminergic neurons to the combined toxicity caused by L‐buthionine sulfoximine and 1‐methyl‐4‐phenylpyridine , 2000, Journal of neuroscience research.
[60] A. Howie,et al. Extrarenal Expression of 25-Hydroxyvitamin D3-1α-Hydroxylase1 , 2001 .
[61] S. Brimijoin,et al. Effects of 1,25-dihydroxyvitamin D3 on growth of mouse neuroblastoma cells. , 1997, Brain research. Developmental brain research.
[62] R. Tardiman,et al. Hip fractures in patients with Parkinson's syndrome. , 1983, The Journal of trauma.
[63] K. Radhakrishnan,et al. Epidemiology of Parkinson's disease in Benghazi, North-East Libya , 1986, Clinical Neurology and Neurosurgery.
[64] S. Emans,et al. Prevalence of vitamin D deficiency among healthy adolescents. , 2004, Archives of pediatrics & adolescent medicine.
[65] K. Dodd,et al. Use of vitamin, mineral, nonvitamin, and nonmineral supplements in the United States: The 1987, 1992, and 2000 National Health Interview Survey results. , 2004, Journal of the American Dietetic Association.
[66] P. Lips. Which circulating level of 25-hydroxyvitamin D is appropriate? , 2004, The Journal of Steroid Biochemistry and Molecular Biology.
[67] R. Lea,et al. VARIATION IN THE VITAMIN D RECEPTOR GENE IS ASSOCIATED WITH MULTIPLE SCLEROSIS IN AN AUSTRALIAN POPULATION , 2005, Journal of neurogenetics.
[68] A. Kalueff,et al. Increased anxiety in mice lacking vitamin D receptor gene , 2004, Neuroreport.
[69] W. Stumpf,et al. OH ) 2 vitamin D 3 sites of action in the brain An autoradiographic study , 2022 .
[70] P. Huet,et al. Apparent [3H]1,25-dihydroxyvitamin D3 uptake by canine and rodent brain. , 1983, The American journal of physiology.
[71] H. Cross,et al. Vitamin D and calcium deficits predispose for multiple chronic diseases , 2005, European journal of clinical investigation.
[72] W. Willett,et al. Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes. , 2006, The American journal of clinical nutrition.
[73] G. Rice,et al. A pilot study of oral calcitriol (1,25-dihydroxyvitamin D3) for relapsing–remitting multiple sclerosis , 2005, Journal of Neurology, Neurosurgery & Psychiatry.
[74] L. Svenson,et al. Geographic Variations in the Prevalence Rates of Parkinson’s Disease in Alberta , 1993, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.
[75] H. Pols,et al. Vitamin D , 1928, Calcified Tissue International.
[76] R. Perez-Fernandez,et al. 1,25-Dihydroxyvitamin D(3) increases striatal GDNF mRNA and protein expression in adult rats. , 2002, Brain research. Molecular brain research.
[77] H. Kim. Finite-amplitude surface waves on a thin film flow subject to a unipolar-charge injection , 2005 .
[78] R. Houlgatte,et al. 1,25‐Dihydroxyvitamin D3 is a potent inducer of nerve growth factor synthesis , 1991, Journal of neuroscience research.
[79] E. Gunter,et al. Hypovitaminosis D in medical inpatients. , 1998, The New England journal of medicine.
[80] K. Prufer,et al. Vitamin D receptor and retinoid X receptor interactions in motion. , 2002, Vitamins and hormones.
[81] M. Campbell,et al. Biological actions of extra-renal 25-hydroxyvitamin D-1α-hydroxylase and implications for chemoprevention and treatment , 2005, The Journal of Steroid Biochemistry and Molecular Biology.
[82] M. Haussler,et al. Immunocytochemical localization of the 1,25-dihydroxyvitamin D3 receptor in target cells. , 1988, Endocrinology.
[83] D. Eyles,et al. Vitamin D receptor expression in the embryonic rat brain , 2003 .
[84] Anthony W. Norman,et al. Steroid-hormone rapid actions, membrane receptors and a conformational ensemble model , 2004, Nature Reviews Drug Discovery.
[85] A. Mackay-Sim,et al. Behavioural characterization of Vitamin D receptor knockout mice , 2005, Behavioural Brain Research.
[86] J. Templeton,et al. Hip fractures in patients with Parkinson's disease. , 1980, Clinical orthopaedics and related research.
[87] M. Holick,et al. 25-hydroxyvitamin D-1α-hydroxylase in normal and malignant colon tissue , 2001, The Lancet.
[88] R. Heaney,et al. Long-latency deficiency disease: insights from calcium and vitamin D. , 2003, The American journal of clinical nutrition.
[89] C. Kao,et al. A comparative study of 99Tcm‐HMPAO and 99Tcm‐ECD as a leukocyte labelling agent , 1994, Nuclear medicine communications.
[90] C. Polman,et al. Multiple sclerosis and vitamin D: an update , 2004, European Journal of Clinical Nutrition.
[91] Yoshihiro Sato,et al. High prevalence of vitamin D deficiency and reduced bone mass in Parkinson's disease , 1997 .
[92] F. Ishizaki,et al. Relationship between osteopenia and clinical characteristics of parkinson's disease , 1993, Movement disorders : official journal of the Movement Disorder Society.
[93] Edward Giovannucci,et al. Vitamin D and prevention of colorectal cancer , 2005, The Journal of Steroid Biochemistry and Molecular Biology.
[94] M. Hoehn,et al. Parkinsonism , 1967, Neurology.
[95] O Johnell,et al. Fracture risk in patients with parkinsonism: a population-based study in Olmsted County, Minnesota. , 1992, Age and ageing.